Quick Answer
GeneDx Holdings Corp. reported R&D Expense of $72.03 million for fiscal year 2025.
GeneDx Holdings Corp. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $72.03M | +57.5% |
| 2024 | $45.72M | -21.5% |
| 2023 | $58.27M | -32.4% |
| 2022 | $86.20M | -18.0% |
| 2021 | $105.16M | +44.7% |
| 2020 | $72.70M | +108.2% |
| 2019 | $34.91M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $19.83M | +70.0% | +31.5% |
| June 30, 2025 | $15.08M | +38.3% | +19.9% |
| March 31, 2025 | $12.58M | +8.7% | +7.8% |
| September 30, 2024 | $11.66M | -18.4% | +7.0% |
| June 30, 2024 | $10.90M | -36.4% | -5.7% |
| March 31, 2024 | $11.57M | -20.7% | -19.0% |
| September 30, 2023 | $14.29M | +7.0% | -16.6% |
| June 30, 2023 | $17.14M | -36.9% | +17.4% |
- GeneDx Holdings Corp. showed an increase of +57.5% in R&D Expense compared to the prior fiscal year.
- Over the 2019–2025 period, GeneDx Holdings Corp.’s r&d expense has grown by 106.3% (from $34.91 million to $72.03 million).
- The most recent figure is from GeneDx Holdings Corp.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: